Literature DB >> 28243273

Novel Oxadiazole Thioglycosides as Potential Anti-Acinetobacter Agents.

Karim Akbari Dilmaghani1, Fazel Nasuhi Pur2, Majid Mahammad Pour1, Jafar Mahammad Nejad1.   

Abstract

The glycosylation of 1,3,4-oxadiazole-2-thiones has been performed with peracetylated β-pyranosyl bromide in the presence of potassium carbonate. Deprotection of acetylated thioglycosides was necessary for increasing their antibacterial effects. The structures of nucleosides were confirmed by 1H NMR, 13C NMR and HRMS. The anomeric protons of nucleosides c1-4 were assigned to the doublet, confirming the β-configuration. The synthesized compounds were tested for their antimicrobial activity against Acinetobacter calcoaceticus (Gram-negetive) strain in-vitro in comparison with Ampicillin as a reference drug which is normally used for treating such infections. The synthetic compounds showed different inhibition zones against tested bacterial strain. Thioglycoside derivatives of 1,3,4-oxadiazole-2-thiones (c set) were more active against Acinetobacter calcoaceticus ATCC 23055 than "parent" 1,3,4-oxadiazole-2-thiones (a set), confirming the relation between glyco-conjugation and increasing of antiproliferative activity of antibiotic agents. The best result belonged to nucleoside bearing 2-furyl moiety in its heterocyclic nucleus (c4). The existence of m-PhNO2 group as Ar in structures of a set and their corresponding sugar derivatives decreased the antibacterial activity of them in comparison with the rest of synthetic compounds.

Entities:  

Keywords:  1; 3; 4-Oxadiazole-2-thione; Acinetobacter calcoaceticus; Antiproliferative activity; Nucleoside; Thioglycoside; in-vitro; β-Pyranosyl

Year:  2016        PMID: 28243273      PMCID: PMC5316255     

Source DB:  PubMed          Journal:  Iran J Pharm Res        ISSN: 1726-6882            Impact factor:   1.696


Introduction

The resistance of infective bacteria to present antibiotics demands research assigned to the discovery of new drugsin the antibacterial drug field. The majority of carbohydrates found in nature or biological systems exist as glycoconjugates in which the monosaccharide units are joined via O-, N-, or S-glycosidic bonds. Thioglycosides have received considerable attention, because they are widely employed as biological inhibitors, inducers and ligandsfor affinity chromatography of carbohydrate-processing enzymes and proteins (1-8). They have excellent chemoselectivity in glycosylation processes as both donors and acceptorsparticularly via reaction processesthat involve active and latent glycosylation protocols (9). The thioglycosyl heterocycles are sufficiently stable under a variety of reaction conditions and have the ability to be readilyconverted into a variety of other functionalities (10, 11). Multivalent display of carbohydrates is frequently used as a method to increase affinities in various contexts such as the binding of bacteria, bacterial toxins, galectins and other lectins (12-24). These properties may affect medicinal effect of antibiotic agents. On the other hand, oxadiazole derivatives, which belong to an important group of heterocyclic compounds, have been thesubject of extensive study in the recent past. Numerous reports have highlighted their chemistry anduse. Diverse biological activities, such as antiinflamatory, antitumor, antimicrobial and anticonvulsant, have been found to be associated with oxadiazole derivatives (25-28). Moreover, sulfur-containing heterocycles represent an important group of sulfur compounds that are promising for use in practical applications. General synthetic pathway for the synthesis of thioglycosyl oxadiazoles In-vitro antibacterial activity of synthetic compounds against Acinetobacter Calcoaceticus ATCC 23055 (concentration = 10 µg/µL Therefore, it is interesting to report the synthesis of a new series of compounds in which the glycosyl moieties have been used as carriers for the heterocycles having the oxadiazole ring. In our previous work (29), we reported the synthesis antibacterial properties of new series of thioglycoside derivatives of 1,2,4-triazole-5-thiones, whereas in the present work, we report the synthesisof new groups of anti-Acinetobacter calcoaceticus agents in which 1,3,4-oxadiazole-2-thiones moiety is coupled to monosaccharide unit.

Experimental

1H and 13C NMR spectra were recorded on a Bruker AVANCE-300 spectrometer at 300 and 75 MHz, respectively in CDCl3 using TMS as the internal standard. High-resolutionmass spectra were obtained with a HPLC-Q-TOF system equipped with Q-TOF micromass spectrometer (dual ESI). Melting points were measured on a Philip Harris C4954718apparatus without calibration. Optically active samples were analyzed by EHARTNACKapparatus (Paris, France) at 20 °C in dichloromethane. Thin layer chromatography (TLC) analyses were carried out on silica gel plates. All chemicals were purchased from Merckand used as received. 5-phenyl-1,3,4-oxadiazole-2(3H)-thione (a 1 ) Yield: 74%; mp 158-160 °C; 1H NMR spectrum, (300 MHz, CDCl3), δ, ppm, (J, Hz): ): 7.52 (m, 3H, ArH), 7.96 (d, J = 6.9, 2H, ArH) 10.75 (bs, 1H, N-H); 13C NMR spectrum, (75 MHz, CDCl3), δ, ppm: 122.90, 126.47, 129.85, 132.67, 160.90 (Ar), 177.88 (C=S). 5-(2-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione (a 2 ) Yield: 84%; mp 162-164 °C; 1H NMR spectrum, (300 MHz, CDCl3), δ, ppm, (J, Hz): ): 7.10 (m, 2H, ArH), 7.49 (t, 1H, J = 7.1, ArH), 7.72 (2, 1H, J = 8.1, ArH), 8.39 (bs, 1H, OH), 11.34 (bs, 1H, N-H); 13C NMR spectrum, (75 MHz, CDCl3), δ, ppm: 109.79, 111.17, 119.84, 129.50, 133.87, 156.78, 160.27 (Ar), 177.47 (C=S). 5-(3-nitrophenyl)-1,3,4-oxadiazole-2(3H)-thione (a 3 ) Yield: 78%; mp 167-168 °C; 1H NMR spectrum, (300 MHz, CDCl3), δ, ppm, (J, Hz): ): 7.40-7.60 (m, 3H, ArH), 7.94 (d, J = 7.8, 1H, ArH), 11.10 (bs, 1H, OH); 13C NMR spectrum, (75 MHz, CDCl3), δ, ppm: 120.93, 124.43, 126.85, 131.76, 132.44, 148.53, 159.15 (Ar), 178.04 (C=S) 5-(2-furyl)-1,3,4-oxadiazole-2(3H)-thione (a 4 ) Yield: 69%; mp 152-155 °C; 1H NMR spectrum, (300 MHz, CDCl3), δ, ppm, (J, Hz): ): 6.62 (bs, 1H, Furyl), 7.18 (bs, 1H, Furyl), 7.66 (bs, 1H, Furyl), 11.38 (bs, 1H, N-H); 13C NMR spectrum, (75 MHz, CDCl3), δ, ppm: 113.05, 115.37, 137.99, 147.61, 153.90 (Ar), 177.10 (C=S). 2-phenyl-5-(2,3,4,6-tetra-O-acetyl-β-D-1-thio-glucopyranose)-1,3,4-oxadiazole (b1) Yield: 64%; mp 102-105 °C; 1H NMR spectrum, (300 MHz, CDCl3), δ, ppm, (J, Hz): ): 1.95 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.09 (s, 3H, OAc), 2.18 (s, 3H, OAc), 3.88-3.99 (m, 1H, H-6a), 4.12-4.20 (m, 1H, H-6b), 4.27-4.30 (m, 1H, H-5), 5.14-5.71 (m, 3H, H-2, -3, -4), 5.96 (d, 1H, J1,2 = 9.3, H-1), 7.52 (m, 3H, ArH), 7.94-8.04 (m, 2H, ArH); 13C NMR spectrum, (75 MHz, CDCl3), δ, ppm: 20.56 (2C), 20.72 (2C) (4 × OCOCH3), 61.55 (C-6), 67.56 (C-4), 69.76 (C-2), 73.52 (C-3), 74.71 (C-5), 83.42 (C-1), 121.93, 126.80, 129.18, 132.03, 132.79 (Ar), 166.52 (C−S), 168.93, 168.37, 170.06, 170.58 (4 × OCOCH3). 2-(2-hydroxyphenyl)-5-(2,3,4,6-tetra-O-acetyl-β-D-1-thio-glucopyranose)-1,3,4-oxadiazole (b2) Yield: 66%; mp 99-101 °C; 1H NMR spectrum, (300 MHz, CDCl3), δ, ppm, (J, Hz): ): 2.03 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.06 (s, 3H, OAc), 2.10 (s, 3H, OAc), 3.88-3.92 (m, 1H, H-6a), 4.13-4.17 (m, 1H, H-6b), 4.27-4.32 (m, 1H, H-5), 5.14-5.37 (m, 3H, H-2, -3, -4), 5.50 (d, 1H, J1,2 = 9.6, H-1), 7.02 (t, 1H, J = 7.8, ArH), 7.13 (d, 1H, J = 8.4, ArH), 7.47 (t, 1H, J = 6.9, ArH), 7.72 (d, 1H, J = 7.8, ArH), 9.87 (bs, 1H, OH); 13C NMR spectrum, (75 MHz, CDCl3), δ, ppm: 20.54 (2C), 20.60 (2C) (4 × OCOCH3), 61.56 (C-6), 67.72 (C-4), 69.74 (C-2), 73.46 (C-3), 76.62 (C-5), 83.33 (C-1), 107.58, 117.66, 120.11, 126.54, 134.04, 157.34, 160.02 (Ar), 165.92 (C−S), 169.34, 169.43, 169.966, 170.54 (4 × OCOCH3). 2-(3-nitrophenyl)-5-(2,3,4,6-tetra-O-acetyl-β-D-1-thio-glucopyranose)-1,3,4-oxadiazole (b3) Yield: 58%; mp 112-113 °C; 1H NMR spectrum, (300 MHz, CDCl3), δ, ppm, (J, Hz): ): 2.04 (s, 3H, OAc), 2.06 (s, 3H, OAc), 2.09 (s, 3H, OAc), 2.10 (s, 3H, OAc), 3.88-4.05 (m, 1H, H-6a), 4.14-4.21 (m, 1H, H-6b), 4.28-4.33 (m, 1H, H-5), 5.16-5.67 (m, 3H, H-2, -3, -4), 5.97 (d, 1H, J1,2 = 9.3, H-1), 7.75 (t, J = 7.8, 1H, ArH), 8.27-8.43 (m, 2H, ArH), 8.84 (d, J = 8.1, 1H, ArH); 13C NMR spectrum, (75 MHz, CDCl3), δ, ppm: 20.53 (2C), 20.65 (2C) (4 × OCOCH3), 61.50 (C-6), 67.70 (C-4), 69.71 (C-2), 73.49 (C-3), 74.83 (C-5), 83.32 (C-1), 121.80, 124.93, 126.36, 127.03, 130.52, 132.21, 148.67 (Ar), 164.50 (C-S), 169.33, 169.44, 169.97, 170.53 (4 × OCOCH3). 2-(2-furyl)-5-(2,3,4,6-tetra-O-acetyl-β-D-1-thio-glucopyranose)-1,3,4-oxadiazole (b4) Yield: 72%; mp 107-109 °C; 1H NMR spectrum, (300 MHz, CDCl3), δ, ppm, (J, Hz): ): 1.97 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.07 (s, 3H, OAc), 2.10 (s, 3H, OAc), 3.85-4.00 (m, 1H, H-6a), 4.13-4.21 (m, 1H, H-6b), 4.27-4.32 (m, 1H, H-5), 5.24 (t, 1H, J1,2=J2,3 = 9.3, H-2), 5.42 (t, 1H, J2,3=J3,4 = 9.3, H-4), 5.61 (t, 1H, J2,3=J3,4 = 9.3, H-3), 6.34 (d, 1H, J1,2 = 9.3, H-1), 6.61 (bs, 1H, Furyl), 7.17 (bs, 1H, Furyl), 7.66 (bs, 1H, Furyl); 13C NMR spectrum, (75 MHz, CDCl3), δ, ppm: 20.49 (2C), 20.70 (2C) (4 × OCOCH3), 61.54 (C-6), 67.51 (C-4), 69.40 (C-2), 73.04 (C-3), 74.75 (C-5), 83.17 (C-1), 112.36, 116.17, 137.41, 146.80, 152.37 (Ar), 159.98 (C-S), 168.97, 169.28, 170.04, 170.56 (4 × OCOCH3). 2-phenyl-5-(β-D-1-thio-glucopyranose)-1,3,4-oxadiazole (c1) Yield: 33%; mp 108-110 °C; [α]D20= 3° (c = 1.0, CH2Cl2). 1H NMR spectrum, (300 MHz, CDCl3), δ, ppm, (J, Hz): ): 3.92-4.03 (m, 1H, H-6a), 4.12-4.22 (m, 1H, H-6b), 4.27-4.30 (m, 1H, H-5), 4.35-4.85 (m, 4H, OH), 5.12-5.70 (m, 3H, H-2, -3, -4), 5.99 (d, 1H, J1,2 = 9.3, H-1), 7.50 (m, 3H, ArH), 7.94-8.02 (m, 2H, ArH); 13C NMR spectrum, (75 MHz, CDCl3), δ, ppm: 61.76 (C-6), 67.64 (C-4), 69.26 (C-2), 73.59 (C-3), 74.78 (C-5), 83.37 (C-1), 122.23, 126.88, 129.40, 132.09, 132.99 (Ar), 166.45 (C−S); HRMS spectrum (ESI), m/z: Calculated, 340.0729. C14H16N2O6S [M+H]+. Found, 341.0817. 2-(2-hydroxyphenyl)-5-(β-D-1-thio-glucopyranose)-1,3,4-oxadiazole (c2) Yield: 46%; mp 144-145 °C; [α]D20= 4° (c = 1.0, CH2Cl2). 1H NMR spectrum, (300 MHz, CDCl3), δ, ppm, (J, Hz): ): 3.86-3.97 (m, 1H, H-6a), 4.11-4.16 (m, 1H, H-6b), 4.26-4.32 (m, 1H, H-5), 4.37-4.83 (m, 4H, OH), 5.13-5.37 (m, 3H, H-2, -3, -4), 5.57 (d, 1H, J1,2 = 9.6, H-1), 7.03 (t, 1H, J = 7.8, ArH), 7.12 (d, 1H, J = 8.4, ArH), 7.49 (t, 1H, J = 6.9, ArH), 7.74 (d, 1H, J = 7.8, ArH), 9.97 (bs, 1H, OH); 13C NMR spectrum, (75 MHz, CDCl3), δ, ppm: 62.46 (C-6), 68.02 (C-4), 69.86 (C-2), 73.65 (C-3), 76.69 (C-5), 83.04 (C-1), 109.18, 117.36, 121.01, 126.94, 133.84, 157.86, 160.23 (Ar), 165.57 (C−S); HRMS spectrum (ESI), m/z: Calculated, 356.0678. C14H16N2O7S [M+H]+. Found, 357.0762. 2-(3-nitrophenyl)-5-(β-D-1-thio-glucopyranose)-1,3,4-oxadiazole (c3) Yield: 39%; mp 122-124 °C; [α]D20= -2° (c = 1.0, CH2Cl2). 1H NMR spectrum, (300 MHz, CDCl3), δ, ppm, (J, Hz): ): 3.84-4.01 (m, 1H, H-6a), 4.17-4.25 (m, 1H, H-6b), 4.24-4.33 (m, 1H, H-5), 4.36-4.85 (m, 4H, OH), 5.16-5.68 (m, 3H, H-2, -3, -4), 6.07 (d, 1H, J1,2 = 9.3, H-1), 7.78 (t, J = 7.8, 1H, ArH), 8.27-8.46 (m, 2H, ArH), 8.81 (d, J = 8.4, 1H, ArH); 13C NMR spectrum, (75 MHz, CDCl3), δ, ppm: 62.20 (C-6), 67.74 (C-4), 69.79 (C-2), 73.67 (C-3), 74.35 (C-5), 83.44 (C-1), 121.89, 123.90, 126.86, 127.43, 131.82, 132.28, 149.63 (Ar), 165.22 (C-S); HRMS spectrum (ESI), m/z: Calculated, 385.0580. C14H15N3O8S [M+H]+. Found, 386.0665. 2-(2-furyl)-5-(β-D-1-thio-glucopyranose)-1,3,4-oxadiazole (c4) Yield: 52%; mp 111-113 °C; [α]D20= -4° (c = 1.0, CH2Cl2). 1H NMR spectrum, (300 MHz, CDCl3), δ, ppm, (J, Hz): ): 3.82-4.08 (m, 1H, H-6a), 4.17-4.23 (m, 1H, H-6b), 4.24-4.39 (m, 1H, H-5), 4.35-4.89 (m, 4H, OH), 5.27 (t, 1H, J1,2=J2,3 = 9.3, H-2), 5.45 (t, 1H, J2,3=J3,4 = 9.3, H-4), 5.69 (t, 1H, J2,3=J3,4 = 9.3, H-3), 6.31 (d, 1H, J1,2 = 9.3, H-1), 6.66 (bs, 1H, Furyl), 7.17 (bs, 1H, Furyl), 7.58 (bs, 1H, Furyl); 13C NMR spectrum, (75 MHz, CDCl3), δ, ppm: 60.94 (C-6), 66.98 (C-4), 69.87 (C-2), 73.54 (C-3), 74.85 (C-5), 83.63 (C-1), 112.30, 117.20, 137.83, 146.88, 152.52 (Ar), 162.07 (C-S); HRMS spectrum (ESI), m/z: Calculated, 330.0522. C12H14N2O7S [M+H]+. Found, 331.0609. Bacterial Strain The antibacterial activity of compounds was assayed with our previous published method (30). The antibacterial activity of the compounds was tested against Gram-negative strain of Acinetobacter calcoaceticus ATCC 23055.

Resultsand Discussion

Thioglycosilation was performed according our previous published method (29). 1-bromide sugar and 1,3,4-oxadiazole-2-thione nuclei a1-4 were synthesized to the literature procedures (29,31). Deprotection of acetylated nucleosides was performed to the literature procedure (32). The synthesis of the final nucleosides is depicted in Figure 1.
Figure 1

General synthetic pathway for the synthesis of thioglycosyl oxadiazoles

The structure of thioglycosides was confirmed by appropriate spectroscopic methods such as1HNMR,13C NMR, and high resolution mass spectroscopy (HRMS). The anomeric protons of nucleosides c1–4 were assigned to the doublet at 5.57–6.31 ppm with J1,2=9.3–9.6 Hz, confirming theβ-configuration. In our recent published research (29), there was not any significant change in the antibacterial effect of the acetylated final thioglycosides in comparison with the parent heterocyclic nuclei. Therefore, in the present work, the deacetylated nucleosides c1-4 have been compared to the parent heterocyclic nuclei a1-4 against Acinetobacter calcoaceticus. The in vitro antibacterial activity of the synthesized compounds in DMSO against Acinetobacter calcoaceticus is shown in Tables 1. Diameter of inhibition zone for ampicillin as reference drug is 18 mm for 10 µg/µL concentration of drug in the same test conditions.
Table 1

In-vitro antibacterial activity of synthetic compounds against Acinetobacter Calcoaceticus ATCC 23055 (concentration = 10 µg/µL

Compound Diameter of inhib. zone (mm) Compound Diameter of inhib. zone (mm)
a4 22 c4 31
a 1 19 c 1 28
a 2 18 c 2 29
a 3 16 c 3 25
As shown in the Table 1. these compounds showed higher antibacterial effects in comparison with Ampicillin (18 mm) which is normally used for treating such infections. In general, compounds from c set (nucleosides) showed more antimicrobial activity than the other set. Thioglycoside derivatives of 1,3,4-oxadiazole-2-thiones (c set) were more active against Acinetobacter calcoaceticus ATCC 23055 than “parent” 1,3,4-oxadiazole-2-thiones (a set), confirming the relation between glyco-conjugation and increasing of antiproliferative activity of antibiotic agents. The best results in the tables belonged to c4that showing high activity against A. calcoaceticus (31 mm). Going over the structure of these synthetic compounds confirmed that the existence of 2-furyl instead of m-PhNO2 group as Ar increased their antibacterial activity against A. calcoaceticus. The existence of m-PhNO2 group as Ar in structures of a set and their corresponding sugar derivatives decreased the antibacterial activity of them in comparison with the rest of synthetic compounds.
  23 in total

Review 1.  Affinity enhancement by multivalent lectin-carbohydrate interaction.

Authors:  R T Lee; Y C Lee
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 2.916

2.  Adhesion inhibition of F1C-fimbriated Escherichia coli and Pseudomonas aeruginosa PAK and PAO by multivalent carbohydrate ligands.

Authors:  Reshma Autar; A Salam Khan; Matthias Schad; Jörg Hacker; Rob M J Liskamp; Roland J Pieters
Journal:  Chembiochem       Date:  2003-12-05       Impact factor: 3.164

3.  Spatial screening of cyclic neoglycopeptides: identification of polyvalent wheat-germ agglutinin ligands.

Authors:  Valentin Wittmann; Sonja Seeberger
Journal:  Angew Chem Int Ed Engl       Date:  2004-02-06       Impact factor: 15.336

4.  Altering the strength of lectin binding interactions and controlling the amount of lectin clustering using mannose/hydroxyl-functionalized dendrimers.

Authors:  Eric K Woller; Eric D Walter; Joel R Morgan; David J Singel; Mary J Cloninger
Journal:  J Am Chem Soc       Date:  2003-07-23       Impact factor: 15.419

5.  Comparative evaluation of D-glucosyl thiouronium, glucosylthio heterocycles, Daonil, and insulin as inhibitors for hepatic glycosidases.

Authors:  Olfat M El din Awad; Wafaa E Attia; El Sayed H El Ashry
Journal:  Carbohydr Res       Date:  2004-02-25       Impact factor: 2.104

6.  Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands.

Authors:  P I Kitov; J M Sadowska; G Mulvey; G D Armstrong; H Ling; N S Pannu; R J Read; D R Bundle
Journal:  Nature       Date:  2000-02-10       Impact factor: 49.962

7.  Wedgelike glycodendrimers as inhibitors of binding of mammalian galectins to glycoproteins, lactose maxiclusters, and cell surface glycoconjugates.

Authors:  S André; R J Pieters; I Vrasidas; H Kaltner; I Kuwabara; F T Liu; R M Liskamp; H J Gabius
Journal:  Chembiochem       Date:  2001-11-05       Impact factor: 3.164

8.  Synthesis and structure determination of some oxadiazole-2-thione and triazole-3-thione galactosides.

Authors:  R Ahmad; R Iqbal; H Akhtar; H Duddeck; L Stefaniak; J Sitkowski
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2001-09       Impact factor: 1.381

9.  Rigidified multivalent lactose molecules and their interactions with mammalian galectins: a route to selective inhibitors.

Authors:  Ioannis Vrasidas; Sabine André; Paola Valentini; Corina Böck; Martin Lensch; Herbert Kaltner; Rob M Liskamp; Hans-J Gabius; Roland J Pieters
Journal:  Org Biomol Chem       Date:  2003-03-07       Impact factor: 3.876

10.  Inhibition of adhesion of type 1 fimbriated Escherichia coli to highly mannosylated ligands.

Authors:  Noriko Nagahori; Reiko T Lee; Shin-Ichiro Nishimura; Daniel Pagé; René Roy; Yuan C Lee
Journal:  Chembiochem       Date:  2002-09-02       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.